Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2025 Vol. 3 > No. 1 > 100119
Next Article Previous Article
NEWS & BUZZ   Open Access     Cite

Chimeric Antigen Receptor T-cell therapy in pediatric refractory systemic lupus erythematosus

  • 1.

    Department of Nephrology, Children’s Hospital, Zhejiang University School of Medicine, National clinical research center for child health, Hangzhou 310052, China

  • 2.

    Department of Allergy Immunology and Rheumatology, Children’s Hospital, Zhejiang University School of Medicine, National clinical research center for child health, Hangzhou 310052, China

  • 3.

    Chongqing Precision Biotech Co., Ltd., Chongqing 400039, China

More Information
  • Corresponding author: maojh88@zju.edu.cn
  • Received Date:  December 15, 2024
    Accepted Date:  February 19, 2025
    Published Online:  February 21, 2025
The Innovation Medicine  3(1),  https://doi.org/10.59717/j.xinn-med.2025.100119  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Charras A., Smith E. and Hedrich C. M. (2021). Systemic lupus erythematosus in children and young people. Curr. Rheumatol. Rep. 23:20 DOI:10.1007/s11926-021-00985-0

    View in Article CrossRef Google Scholar

    [2] Mougiakakos D., Krönke G., Völkl S., et al. (2021). CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385:567−569 DOI:10.1056/NEJMc2107725

    View in Article CrossRef Google Scholar

    [3] Schett G., Müller F., Taubmann J., et al. (2024). Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20:531−544 DOI:10.1038/s41584-024-01139-z

    View in Article CrossRef Google Scholar

    [4] Atisha-Fregoso Y., Malkiel S., Harris K. M., et al. (2021). Phase II randomized trial of rituximab plus cyclophosphamide followed by Belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 73:121−131 DOI:10.1002/art.41466

    View in Article CrossRef Google Scholar

    [5] He X., Hu B., Zhang Y., et al. (2025). Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun. Rev. 24:103692 DOI:10.1016/j.autrev.2024.103692

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    He X., Liu F., Lu M., et al. (2025). Chimeric Antigen Receptor T-cell therapy in pediatric refractory systemic lupus erythematosus. The Innovation Medicine 3:100119. https://doi.org/10.59717/j.xinn-med.2025.100119
    He X., Liu F., Lu M., et al. (2025). Chimeric Antigen Receptor T-cell therapy in pediatric refractory systemic lupus erythematosus. The Innovation Medicine 3:100119. https://doi.org/10.59717/j.xinn-med.2025.100119

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3940) PDF downloads(2407)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.